Corient IA LLC Invests $570,000 in Eli Lilly and Company $LLY

Key Points

• Corient IA LLC acquired 690 shares of Eli Lilly and Company, valued at approximately $570,000, during the 1st quarter of the year.
• Eli Lilly reported a strong earnings performance with $6.31 EPS for the quarter, exceeding analysts' expectations of $5.59 and a year-over-year revenue increase of 37.6%.
• The company has also announced a quarterly dividend of $1.50 per share, representing an annualized yield of 0.9%, to be paid on September 10th.

Corient IA LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 690 shares of the company's stock, valued at approximately $570,000.

Other hedge funds have also bought and sold shares of the company. Redwood Investments LLC grew its holdings in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after purchasing an additional 12 shares during the last quarter. Hobbs Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Finally, Ascent Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after purchasing an additional 12 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Up 0.8%

Shares of LLY stock traded up $5.5170 during trading hours on Tuesday, reaching $703.5670. 5,929,987 shares of the company's stock were exchanged, compared to its average volume of 6,686,759. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $665.90 billion, a PE ratio of 45.98, a PEG ratio of 0.97 and a beta of 0.44. The stock's fifty day moving average price is $763.06 and its two-hundred day moving average price is $793.64.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Morgan Stanley restated an "overweight" rating and set a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.